Abstract
This chapter will summarise some of the recent advances in cancer pharmacogenomics and how new technologies and study designs may provide important insights to provide safer and more effective treatments for cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Board RE, Williams VS, Knight L et al (2008) Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann N Y Acad Sci. 1137:98–107
Check Hayden E (2009) Personalized cancer therapy gets closer. Nature 458:131–132
Chen CY, Shiesh SC, Wu SJ (2004) Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. Clin Chem 50:481–489
Chowdhury J, Kagiala GV, Pushpakom S et al (2007) Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn 9:521–529
Frueh FW, Amur S, Mummaneni P et al (2008) Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28:992–998
Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111
Leeder JS, Pearce R, Gaedigk A, Modak A, Rosen D (2008). Evaluation of the [13C]-DM breath test to assess CYP2D6 phenotype. J Clin Pharm 48:2041–2051
Maheswaran S, Sequist LV, Nagrath S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366–377
Mattison L, Hany Ezzeldin H, Carpenter M, Modak A, Johnson M, Diasio R (2004) Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-Uracil breath test. Clin Can Res 10:2652–2658
Mok T, Wu Y, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med 361:947–957
Sos ML, Michel K, Zander T et al (2009) Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119:1727–1740
Thomas RK, Nickerson E, Simons JF et al (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12:852–855
Yen JL, McLeod HL (2007) Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 43:1011–1016
Zou H, Taylor WR, Harrington JJ et al (2009) High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136:459–470
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Newman, W.G. (2010). Future Advances in Cancer Pharmacogenomics. In: Newman, W. (eds) Pharmacogenetics: Making cancer treatment safer and more effective. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-8618-1_13
Download citation
DOI: https://doi.org/10.1007/978-90-481-8618-1_13
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-8617-4
Online ISBN: 978-90-481-8618-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)